| abstract |
An object of the present invention is to provide a low-molecular compound (IL-17 activity inhibitor) having an IL-17 activity inhibitory ability superior to that of the prior art. IL-17RA inhibitors of the present invention are, for example, Phe60, Gln87, Asp121, Pro122, Asp123, Gln124, Asp153, Cys154, Glu155, which are contained in the extracellular domain of human interleukin 17 receptor A (IL-17RA). In the space surrounded by Lys160, Pro164, Cys165, Ser167, Ser168, Gly169, Ser170, Leu171, Trp172, Asp173, Pro174, Pro254, Phe256, Ser258, Cys259, Asp262, Cys263, Leu264 and His266, at least of those amino acid residues A group consisting of an ionic bond, a hydrogen bond, a CH-π interaction, and a hydrophobic interaction, including the Van der Waals force acting between 13 and a predetermined one of these amino acid residues. Inhibits the binding of interleukin-17A (IL-17A) to IL-17RA, such as humans, capable of binding to IL-17RA by a non-covalent interaction, including at least one intermolecular interaction selected from It contains a compound having a function, or a pharmaceutically acceptable salt, solvate, or prodrug thereof. |